



HAL
open science

Viral dynamics of delayed CTL-inclusive HIV-1 infection model with both virus-to-cell and cell-to-cell transmissions

Martin Luther Mann Manyombe, Joseph Mbang, Léontine Nkague Nkamba,
Denis Fils Nkoa Onana

► To cite this version:

Martin Luther Mann Manyombe, Joseph Mbang, Léontine Nkague Nkamba, Denis Fils Nkoa Onana. Viral dynamics of delayed CTL-inclusive HIV-1 infection model with both virus-to-cell and cell-to-cell transmissions. 2019. hal-02145903

HAL Id: hal-02145903

<https://hal.science/hal-02145903v1>

Preprint submitted on 3 Jun 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1. Introduction

Research on HIV/AIDS infection is performed in various domains including mathematical modelling. The mathematical modelling is about modelling the evolution of the disease using mathematical tools, mainly differential equations. Over the recent years, great efforts have been paid in mathematical modeling of within-host virus dynamics. Mathematical models have been developed to describe the in vivo infection process of many viruses such as human immunodeficiency virus type I (HIV-I), hepatitis C virus (HCV), hepatitis B virus (HBV), and human T-cell lymphotropic virus I (HTLV-I) [11, 12, 9, 2, 17, 6, 5]. These within-host models are useful for exploring possible mechanisms and outcomes of the viral infection process [11, 12], and for estimating key parameter values such as virion clearance rate, life span of infected cells, and average viral generation time in vivo [9].

Mathematical models and their analysis are helpful in understanding the dynamical behavior of many human viruses such as HIV, HTLV-I and HBV (e.g., [3, 7, 8, 15, 16, 19]). Recently, it has been reported that the uninfected cells can also become infected because of direct contact with infected cells. The viral infection model with cell-to-cell transmission and distributed time delay have been proposed in [3, 7, 16, 18]. They observed that the basic reproduction number of their model might be undervalued if either cell-to-cell spread or virus-to-cell infection is neglected.

Note that the immune response after viral infection is common and is necessary for eliminating or controlling the disease. In most virus infections, cytotoxic T lymphocytes (CTLs) play a critical role in antiviral defense by attacking virus-infected cell. Many existing mathematical models for HIV infection with CTLs response are given by systems of ordinary differential equation (ODE) (see, e.g. [3, 8, 15, 16, 19]). However, time delays can not be ignored when modeling immune response, since antigenic stimulation generating CTLs may need a period of time, that is, the activation rate of CTL response at time t may depend on the population of antigen at a previous time [19]. Moreover, all the aforementioned works not take into account of the constant production rate of CTLs exported from thymus. This consideration of export rate of new CTLs from thymus is considered in [8, 13, 14, 15] and is ignored by many authors.

Motivated by the works in [3, 8, 13, 18], in the present paper, we are concerned by the effect of both virus-to-cell and cell-to-cell transmissions with intracellular delays, and immune response activation delay on the global dynamics of HIV-1 infection model. We consider a within-host viral infection model with both virus-to-cell and cell-to-cell transmissions, immune response and four distributed delays, in which the first, second and fourth delay respectively describes the intracellular latency for virus-to-cell infection, the intracellular latency for the cell-to-cell infection and the time period that viruses penetrated into cells and infected cells release new virions [18], and the third delay describes

the activation delay of CTLs cells ([19]). The rest of the paper is organized as follows. In Section 2, the mathematical model is constructed. Preliminaries including the positivity and boundedness of solutions are introduced in Section 3. In Section 4, the existence of infection-free equilibrium and its global stability are studied. Existence of a chronic infection equilibrium and its global stability with intracellular delays only are presented in Section 5. Furthermore, in this section, we find sufficient conditions for the occurrence of a Hopf bifurcation includes only the immune response delay. In section 6, numerical simulations for several cases of the main model are presented. We further explore the delays and their effects on the stability of the chronic infection equilibrium. Section 7 concludes the paper.

2. The model formulation

The compartmental model includes the concentrations of healthy target cells $T(t)$ which susceptible to infection, infected cells $T_i(t)$ that produces viruses, cytotoxic T lymphocytes (CTLs) cells $T_c(t)$ which are responsible of the destruction of infected cells and viruses $V(t)$. Let β_1 be the virus-to-cell infection rate, β_2 be the cell-to-cell infection rate, δ , μ_1 , α and c be death rates of healthy target cells, activated infected cells, cytotoxic CTLs cells and viruses, respectively. Let b be the production rate of healthy target cells, λ be the production rate of CTLs cells export from thymus, a be the proliferation rate of CTLs cells. Infected cells are eliminated by CTLs cells at a rate q , which represent the lytic activity of CTLs cells. $e^{-\mu_1 s_1}$ is the survival rate of cells that are infected by viruses at time t and become activated s_1 time later with a probability distribution $f_1(s_1)$. Then $\int_0^{\infty} \beta_1 T(t-s_1)V(t-s_1)f_1(s_1)e^{-\mu_1 s_1} ds_1$ describes the newly activated infected target cells which are infected by free viruses s_1 time ago [18]. Similarly, $\int_0^{\infty} \beta_2 T(t-s_2)T_i(t-s_2)f_2(s_2)e^{-\mu_1 s_2} ds_2$ represents the newly activated infected target cells which are infected by infected cells s_2 time ago [18]. $e^{-\mu_2 s_3}$ is the survival rate of CTLs cells that are activated at time t , and become cytotoxic s_3 time later with a probability distribution $f_3(s_3)$. Then, $\int_0^{\infty} a T_i(t-s_3)T_c(t-s_3)f_3(s_3)e^{-\mu_2 s_3} ds_3$ represents the newly CTLs cells proliferated at time t [19]. Let s_4 be the random variable that is the time between viral RNA transcript and viral release and maturation with a probability distribution $f_4(s_4)$. Then, $\int_0^{\infty} k T_i(t-s_4)f_4(s_4)e^{-\mu_3 s_4} ds_4$ describes the mature viral particles produced at time t [18]. k is the average number of viruses that bud out from an infected cell and $e^{-\mu_3 s_4}$ is the survival rates of cells that start budding from activated infected cells at time t and become free mature viruses s_4 time later. Note that s_1, s_2, s_3 and s_4 are

all integration variables, without loss of generality, they all will be represented by s . The model is given as follows :

$$\left\{ \begin{array}{l} \frac{dT(t)}{dt} = b - \delta T - \beta_1 TV - \beta_2 TT_i \\ \frac{dT_i(t)}{dt} = \int_0^\infty \beta_1 T(t-s)V(t-s)f_1(s)e^{-\mu_1 s} ds \\ \quad + \int_0^\infty \beta_2 T(t-s)T_i(t-s)f_2(s)e^{-\mu_1 s} ds - \mu_1 T_i - qT_i T_c \\ \frac{dT_c(t)}{dt} = \lambda + a \int_0^\infty T_i(t-s)T_c(t-s)f_3(s)e^{-\mu_2 s} ds - \alpha T_c \\ \frac{dV(t)}{dt} = k \int_0^\infty T_i(t-s)f_4(s)e^{-\mu_3 s} ds - cV, \end{array} \right. \quad (1)$$

$f_i(\nu) : [0, \infty) \rightarrow [0, \infty)$ are probability distributions with compact support, $f_i(\nu) \geq 0$, and $\int_0^\infty f_i(\nu)d\nu = 1$, $i = 1, \dots, 4$.

From the modeling perspective, the model (1) extends the basic model developed in [8] by : **(i)** incorporating the cell-to-cell transmission, **(ii)** intracellular delays and **(iii)** immune activation delay. Together with this latter improvement **(iii)**, the incorporation of a constant production rate of CTLs export from thymus in our model also extend the works in [3, 16, 19]. It is also noticeable that, our model extends the models developed in [7, 18] by including CTL response immune delay.

3. Preliminaries

Define the Banach space of fading memory type (see [7, 18]) $\mathcal{C} = \{ \phi \in C((-\infty, 0] | \phi(\theta) e^{\mu\theta} \text{ is continuous for } \theta \in (-\infty, 0] \text{ and } \|\phi\| < \infty) \}$ where μ is positive constant and the norm $\|\phi\| = \sup_{\theta \leq 0} |\phi(\theta)| e^{\mu\theta}$. The nonnegative cone of \mathcal{C} is defined by $\mathcal{C}_+ = \mathcal{C}((-\infty, 0], \mathbb{R}_+)$. For $\phi \in \mathcal{C}$, Let $\phi_t(\theta) = \phi(t + \theta)$, $\theta \in (-\infty, 0]$. We consider solutions (T, T_i, T_c, V) of system (1) with initial conditions

$$(T(0), T_i(0), T_c(0), V(0)) \in X := \mathcal{C}_+ \times \mathcal{C}_+ \times \mathcal{C}_+ \times \mathcal{C}_+. \quad (2)$$

By the standard theory of functional differential equations, we can obtain the existence of solutions for $t > 0$. Let

$$\eta_i = \int_0^\infty e^{-\mu_1 s} f_i(s) ds, \quad i = 1, 2, \eta_3 = \int_0^\infty f_3(s) e^{-\mu_3 s} ds, \quad \eta_4 = \int_0^\infty f_4(s) e^{-\mu_4 s} ds.$$

Theorem 3.1 *Solutions of system (1) with initial conditions (2) are positive and ultimately uniformly bounded for $t > 0$.*

Proof 3.1 Let $m(t) = \delta + \beta_1 V(t) + \beta_2 T_i(t)$ and $d(t) = \mu_1 + qT_c(t)$. Let $r(t)$ be the sum of the two integral terms in the second equation of system (1) and $n(t)$ be the integral term in the fourth equation of system (1). From the first equation in (1), we have

$$T(t) = T(0)e^{-\int_0^t m(\xi)d\xi} + \int_0^t e^{-\int_\xi^t m(\theta)d\theta} b d\xi > 0 \quad \text{for } t \geq 0.$$

From the third equation in (1), it follows that $\liminf_{t \rightarrow \infty} T_c(t) \geq \frac{\lambda}{\alpha} > 0$.

From the second and fourth equation in (1), we then have

$$T_i(t) = T_i(0)e^{-\int_0^t d(\xi)d\xi} + \int_0^t r(\xi)e^{-\int_\xi^t d(\theta)d\theta} d\xi \quad \text{and} \quad V(t) = \left[V(0) + \int_0^t n(\xi)e^{c\xi} d\xi \right] e^{-ct},$$

which yield that $T_i(t) > 0$, $V(t) > 0$ for small $t > 0$. Now we prove that $T_i(t) > 0$ and $V(t) > 0$ for all $t > 0$. Otherwise, there exists $t_1 > 0$ such that $\min\{T_i(t_1), V(t_1)\} = 0$. If $T_i(t_1) = 0$, $T_i(t) > 0$ for $0 \leq t < t_1$, and $V(t) > 0$ for $0 \leq t < t_1$, then we have $\frac{dT_i(t_1)}{dt} > 0$. This contradicts $T_i(t_1) = 0$ and $T_i(t) > 0$ for $0 \leq t < t_1$. If $V(t_1) = 0$, $V(t) > 0$ for $0 \leq t < t_1$, and $T_i(t) > 0$ for $0 \leq t < t_1$, then we obtain $\frac{dV(t_1)}{dt} > 0$, which is also a contradiction. Hence, $T_i(t) > 0$ and $V(t) > 0$ for all $t > 0$.

To prove boundedness, first by the positivity of solutions we have $\frac{dT(t)}{dt} < b - \delta T(t)$. It follows that $\limsup_{t \rightarrow \infty} T(t) \leq \frac{b}{\delta}$, implying $T_s(t)$ is bounded. Let

$$G_1(t) = \int_0^\infty f_1(s)e^{-\mu_1 s} T(t-s) ds + \int_0^\infty f_2(s)e^{-\mu_1 s} T(t-s) ds + T_i(t).$$

Since $T(t)$ is bounded and $\int_0^\infty f(u)du$ is convergent, the integral in $G(t)$ is well defined and differentiable with respect to t . Moreover, when taking the time derivative of $G(t)$, the order of the differentiation and integration can be switched. Thus, we have

$$\begin{aligned} \dot{G}_1(t) &= b(\eta_1 + \eta_2) - \delta \int_0^\infty f_1(s)e^{-\mu_1 s} T(t-s) ds - \delta \int_0^\infty f_2(s)e^{-\mu_1 s} T(t-s) ds \\ &\quad - \mu_1 T_i - qT_i T_c, \\ &\leq b(\eta_1 + \eta_2) - \delta \int_0^\infty f_1(s)e^{-\mu_1 s} T(t-s) ds - \delta \int_0^\infty f_2(s)e^{-\mu_1 s} T(t-s) ds \\ &\quad - \left(\mu_1 + \frac{q\lambda}{\alpha} \right) T_i(t) \leq b(\eta_1 + \eta_2) - d_1 G_1(t), \end{aligned}$$

where $d_1 = \min\left\{ \delta, \mu_1 + \frac{q\lambda}{\alpha} \right\}$. Therefore, $\limsup_{t \rightarrow \infty} G_1(t) \leq \frac{b(\eta_1 + \eta_2)}{d_1} := M_1$, implying that $\limsup_{t \rightarrow \infty} T_i(t) \leq M_1$. Then, from the fourth equation of system (1), we have

$$\dot{V}(t) = k \int_0^\infty e^{-\mu_4 s} f_4(s) T_i(t-s) ds - cV \leq kM_1\eta_4 - cV.$$

Thus, $\limsup_{t \rightarrow \infty} V(t) \leq \frac{kM_1\eta_4}{c} := M_2$. Now determine the upper bound of $T_c(t)$. Let

$$G_2(t) = \int_0^\infty f_3(s)e^{-\mu_3 s} T_i(t-s) ds + \frac{q}{a} T_c(t).$$

Thus, we have

$$\begin{aligned} \dot{G}_2(t) &= \int_0^\infty f_3(s)e^{-\mu_3 s} r(t-s) ds - \mu_1 \int_0^\infty f_3(s)e^{-\mu_3 s} T_i(t-s) ds + \frac{q\lambda}{a} - \alpha \frac{q}{a} T_c(t), \\ &\leq \frac{b\eta_3}{\delta} (\beta_1 \eta_1 M_2 + \beta_2 \eta_2 M_1) + \frac{q\lambda}{a} - \mu_1 \int_0^\infty f_3(s)e^{-\mu_3 s} T_i(t-s) ds - \alpha \frac{q}{a} T_c(t), \\ &\leq d_2 - d_3 G_2(t), \end{aligned}$$

where

$$d_2 = \frac{b\eta_3}{\delta} (\beta_1 \eta_1 M_2 + \beta_2 \eta_2 M_1) + \frac{q\lambda}{a} \quad \text{and} \quad d_3 = \{\alpha, \mu_1\}.$$

Hence, $\limsup_{t \rightarrow \infty} G_2(t) \leq \frac{d_2}{d_3} := M_3$, implying that $\limsup_{t \rightarrow \infty} T_c(t) \leq \frac{a}{q} M_3$. Thus, $T(t)$, $T_i(t)$, $T_c(t)$ and $V(t)$ are uniformly bounded. \square

Theorem 3.1 implies that omega limit sets of system (1) are contained in the following bounded feasible region :

$$\Omega = \left\{ (T, T_i, T_c, V) \in \mathcal{C}_+^4 : \|T_s\| \leq \frac{b}{\delta}, \|T_i\| \leq M_1, \frac{\lambda}{\alpha} \leq T_c \leq \frac{a}{q} M_3, \|V\| \leq M_2 \right\}.$$

It can be verified that the region Ω is positively invariant with respect (1) and the system is well posed.

4. The infection-free equilibrium and its stability

System (1) has an infection-free equilibrium $E_0 = (\frac{b}{\delta}, 0, \frac{\lambda}{\alpha}, 0)$. We defined the basic reproduction number as follows :

$$\mathcal{R}_0 = \mathcal{R}_{01} + \mathcal{R}_{02} = \frac{k\beta_1 b \eta_1 \eta_4}{c\delta \left(\mu_1 + \frac{q\lambda}{\alpha} \right)} + \frac{\beta_2 b \eta_2}{\delta \left(\mu_1 + \frac{q\lambda}{\alpha} \right)},$$

which represents the average number of secondary infections. In fact, $\frac{k\beta_1 b \eta_1 \eta_4}{c\delta \left(\mu_1 + \frac{q\lambda}{\alpha} \right)}$ is the average number of secondary viruses caused by a virus, that is the basic reproduction number corresponding to virus-to-cell infection mode, while $\frac{\beta_2 b \eta_2}{\delta \left(\mu_1 + \frac{q\lambda}{\alpha} \right)}$ is the average

number of secondary infected cells that caused by an infected cell, that is the basic reproduction number corresponding to cell-to-cell infection mode. The factors have the biological interpretations as follows :

- $\frac{b\beta_1\eta_1}{\delta}$ is the number of new infections caused by a virus in target susceptible cells ;
- $\frac{q\lambda}{\alpha}$ is the rate at which infected cells are eliminated by the CTLs response ;
- $\frac{1}{\mu_1 + \frac{q\lambda}{\alpha}}$ is the average time that an infectious cell survives ;
- $k\eta_4$ is the rate at which infected cells bud into viruses ;
- $\frac{1}{c}$ is gives the average life-span of a virus ;
- $\frac{b\beta_2\eta_2}{\mu_1 + \frac{q\lambda}{\alpha}}$ represents the number of new infections caused by an infected cell in target susceptible cells.

The result below follows is straightforward.

Theorem 4.1 *The infection-free equilibrium E_0 of system (1) is locally asymptotically stable in the feasible region Ω whenever $\mathcal{R}_0 < 1$ and unstable otherwise.*

Proof 4.1 *The characteristic equation of system (1) at the equilibrium E_0 is*

$$(\nu + \delta)(\nu + \alpha) \left[(\nu + c) \left(\nu + \mu_1 + \frac{q\lambda}{\alpha} - \frac{b\beta_2\bar{\eta}_2}{\delta} \right) - \frac{kb\beta_1}{\delta} \bar{\eta}_1 \bar{\eta}_4 \right] = 0, \quad (3)$$

where $\bar{\eta}_i = \int_0^\infty e^{-(\mu_1+\nu)s} f_i(s) ds$, $i = 1, 2$, $\bar{\eta}_3 = \int_0^\infty e^{-(\mu_2+\nu)s} f_3(s) ds$ and $\bar{\eta}_4 = \int_0^\infty e^{-(\mu_3+\nu)s} f_4(s) ds$. We see that (3) has eigenvalues $\nu_1 = -\delta$, $\nu_2 = -\alpha$ and other eigenvalues are determined by

$$(\nu + c) \left(\nu + \mu_1 + \frac{q\lambda}{\alpha} - \frac{b\beta_2\bar{\eta}_2}{\delta} \right) - \frac{kb\beta_1}{\delta} \bar{\eta}_1 \bar{\eta}_4 = 0,$$

which equivalent to

$$\Psi(\nu) := \left(\frac{\nu}{\mu_1 + \frac{q\lambda}{\alpha}} + 1 \right) (\nu + c) - \mathcal{R}_0 \left(\frac{\bar{\eta}_2 \mathcal{R}_{02}}{\eta_2 \mathcal{R}_0} \nu + c \frac{\bar{\eta}_2 \mathcal{R}_{02}}{\eta_2 \mathcal{R}_0} + c \frac{\bar{\eta}_1 \bar{\eta}_4 \mathcal{R}_{01}}{\eta_1 \eta_4 \mathcal{R}_0} \right) = 0. \quad (4)$$

Thus, $\Psi(0) = c(1 - \mathcal{R}_0) < 0$ when $\mathcal{R}_0 > 1$. Note that

$$\bar{\eta}_i \leq \int_0^\infty f_i(s) ds = 1, i = 1, 2, 3, 4.$$

Then, we have

$$\Psi(\nu) \geq \left(\frac{\nu}{\mu_1 + \frac{q\lambda}{\alpha}} + 1 \right) (\nu + c) - \mathcal{R}_0 \left(\frac{\mathcal{R}_{02}}{\eta_2 \mathcal{R}_0} \nu + c \frac{\mathcal{R}_{02}}{\eta_2 \mathcal{R}_0} + c \frac{\mathcal{R}_{01}}{\eta_1 \eta_4 \mathcal{R}_0} \right) \rightarrow +\infty,$$

as $\nu \rightarrow +\infty$. This yields that equation (4) has at least one positive root. Therefore, the infection-free equilibrium E_0 is unstable if $\mathcal{R}_0 > 1$. \square

Biologically speaking, Theorem 4.1 implies that infection can be eliminated if the initial sizes of cells are in the basin of attraction of the infection-free equilibrium. Thus, the infection can be effectively controlled if $\mathcal{R}_0 < 1$. One can remark that \mathcal{R}_0 depends on λ and is a decreasing function of this rate. Hence, the constant rate λ could be an important control parameter in order to reduce \mathcal{R}_0 to a value less than unity. To ensure that the effective control of the infection is independent of the initial size of the cells, a global stability result must be established for the infection-free equilibrium.

Theorem 4.2 *If $\mathcal{R}_0 \leq 1$, then the infection-free equilibrium E_0 of system (1) is globally asymptotically stable in Ω .*

Proof 4.2 *We define a Lyapunov function as follows :*

$$\begin{aligned} L(t) = & T_i + \frac{b\beta_1\eta_1}{c\delta}V + \int_0^\infty f_1(s)e^{-\mu_1s} \int_{t-s}^t \beta_1T(\tau)V(\tau)d\tau ds + \int_0^\infty f_2(s)e^{-\mu_1s} \\ & \int_{t-s}^t \beta_2T(\tau)T_i(\tau)d\tau ds + \frac{b\beta_1\eta_1}{c\delta} \int_0^\infty f_4(s)e^{-\mu_3s} \int_{t-s}^t kT_i(\tau)d\tau ds. \end{aligned}$$

Then the time derivative of $L(t)$ along solutions of system (1) satisfies

$$\frac{dL(t)}{dt} = \beta_1\eta_1TV + \beta_2\eta_2TT_i + \frac{kb\beta_1\eta_1\eta_4}{c\delta}T_i - \mu_1T_i - qT_iT_c - \frac{b\beta_1\eta_1}{\delta}V.$$

Since $T \leq \frac{b}{\delta}$ and $T_c \geq \frac{\lambda}{\alpha}$, we have

$$\frac{dL(t)}{dt} \leq \left[\frac{b\beta_2\eta_2}{\delta} + \frac{kb\beta_1\eta_1\eta_4}{c\delta} - \left(\mu_1 + \frac{q\lambda}{\alpha} \right) \right] T_i = \left(\mu_1 + \frac{q\lambda}{\alpha} \right) (\mathcal{R}_0 - 1)T_i.$$

$\frac{dL(t)}{dt} \leq 0$ whenever $\mathcal{R}_0 \leq 1$. Moreover, $\frac{dL(t)}{dt} = 0 \Leftrightarrow T_i = V = 0$ or $T = \frac{b}{\delta}$, $T_c = \frac{\lambda}{\alpha}$ and $\mathcal{R}_0 = 1$. Thus, the largest invariant set \mathcal{H} such as $\mathcal{H} \subset \left\{ (T, T_i, T_c, V) \in \mathbb{R}_+^4 / \frac{dL(t)}{dt} = 0 \right\}$ is the singleton $\{E_0\}$. By LaSalle's Principle, E_0 is globally asymptotically stable in Ω , completing the proof. \square

5. The chronic infection equilibrium and its stability

5.1. Existence and uniqueness

The existence of a chronic infection equilibrium of the model (1) is addressed when $\mathcal{R}_0 > 1$. The infection is endemic if the infected cells persist above a certain positive level.

Denote by $E^* = (T^*, T_i^*, T_c^*, V^*)$ the chronic infection equilibrium of system (1). At this point, the system (1) satisfies the following relations :

$$\begin{cases} b = \delta T^* + \beta_1 T^* V^* + \beta_2 T^* T_i^* \\ \beta_1 \eta_1 T^* V^* + \beta_2 \eta_2 T^* T_i^* = \mu_1 T_i^* + q T_i^* T_c^* \\ \lambda + a \eta_3 T_i^* T_c^* = \alpha T_c^* \\ k \eta_4 T_i^* = c V^* \end{cases} \quad (5)$$

Solving (5) yields

$$\begin{cases} T^* = \frac{b}{\delta + \left(\beta_1 + \frac{\beta_2 c}{k \eta_4}\right) V^*}, \\ T_c^* = \frac{kb \beta_1 \eta_1 \eta_4 + b \beta_2 \eta_2 c - c \mu_1 \delta - c \mu_1 \left(\beta_1 + \frac{\beta_2 c}{k \eta_4}\right) V^*}{qc \left(\delta + \beta_1 V^* + \frac{\beta_2 c}{k \eta_4} V^*\right)}, \\ T_i^* = \frac{c V^*}{k \eta_4}, \end{cases}$$

where V^* is a positive root of

$$\lambda + a \eta_3 T_i^* T_c^* - \alpha T_c^* = 0. \quad (6)$$

After expansion and substitution of T^* , T_i^* , T_c^* by their expressions, Eq. (6) is equivalent to polynomial

$$P(V) = a_2 V^2 + a_1 V + a_0 = 0, \quad (7)$$

with the coefficients a_2 , a_1 and a_0 given by

$$\begin{aligned} a_2 &= \frac{a \eta_3 c^2 \mu_1}{k \eta_4} \left(\beta_1 + \frac{\beta_2 c}{k \eta_4} \right), \\ a_1 &= \frac{a \eta_3 c^2 \mu_1 \delta}{k \eta_4} - a \eta_3 b c \left(\beta_1 \eta_1 + \frac{\beta_2 \eta_2 c}{k \eta_4} \right) - \left(\beta_1 + \frac{\beta_2 c}{k \eta_4} \right) (\mu_1 c \alpha + q \lambda c), \\ a_0 &= c \delta \alpha \left(\mu_1 + \frac{q \lambda}{\alpha} \right) (\mathcal{R}_0 - 1). \end{aligned} \quad (8)$$

Using $T_c \geq 0$ one shows that $V \leq V_{max}$, where

$$V_{max} = \frac{kb\beta_1\eta_1\eta_4 + b\beta_2\eta_2c - c\mu_1\delta}{c\mu_1\left(\beta_1 + \frac{\beta_2c}{k\eta_4}\right)} = \frac{c\mu_1\delta(\mathcal{R}_0 - 1) + \mathcal{R}_0\frac{c\delta q\lambda}{\alpha}}{c\mu_1\left(\beta_1 + \frac{\beta_2c}{k\eta_4}\right)} > 0.$$

Furthermore, some calculations give

$$P(0) = a_0, \quad P(V_{max}) = -\frac{a_0b\lambda q(k\beta_1\eta_1\eta_4 + \beta_2\eta_2c)}{\mu_1} < 0, \quad \text{and} \quad \lim_{V \rightarrow +\infty} P(V) = +\infty.$$

• If $\mathcal{R}_0 \leq 1$, then $P(0) = a_0 \leq 0$ and the equation $P(V) = 0$ has a unique positive root on $]V_{max}; +\infty[$. Since for all $V \geq V_{max}$, $T_c^* \leq 0$, it follows that system (1) has no positive chronic infection equilibrium in this case.

• If $\mathcal{R}_0 > 1$, then $P(0) = a_0 > 0$ and the equation $P(V) = 0$ has two positive roots : one solution on interval $]0; V_{max}[$ and another solution on $]V_{max}; +\infty[$. Since T_c^* is positive for $0 < V < V_{max}$ and negative for $V > V_{max}$, it follows that system (1) has a unique positive chronic infection equilibrium when $\mathcal{R}_0 > 1$. We have established the following result.

Theorem 5.1 *System (1) always has a infection-free equilibrium E_0 , and*

(i) *if $\mathcal{R}_0 < 1$, system (1) has no positive chronic infection equilibrium ;*

(ii) *if $\mathcal{R}_0 > 1$, system (1) has a unique positive chronic infection equilibrium E^* .*

5.2. Stability analysis of chronic infection equilibrium

On the stability analysis of the chronic infection equilibrium, we only discuss the following special cases : (i) $\tau_i \geq 0$, $i = 1, 2, 4$, $\tau_3 = 0$ and (ii) $\tau_i = 0$, $i = 1, 2, 4$, $\tau_3 > 0$. However, aim at the case $\tau_i > 0$, $i = 1, 2, 3, 4$, the theoretical analysis is very complicated. We will give numerical analysis for this case in the next section.

5.2.1. Global stability of chronic infection equilibrium when $\tau_i \geq 0$, $i = 1, 2, 4$ and $\tau_3 = 0$.

Here, we will prove the global stability of the chronic infection equilibrium of system (1) with $\tau_3 = 0$ by the Lyapunov direct method.

Theorem 5.2 *Consider system (1) with $f_1(s) = f_2(s)$, $\tau_i \geq 0$, $i = 1, 2, 4$ and $\tau_3 = 0$. If $\mathcal{R}_0 > 1$, then the chronic infection equilibrium E^* is globally asymptotically stable.*

Proof 5.1 Consider system (1) with $\tau_i \leq 0$, $i = 1, 2, 4$ and $\tau_3 = 0$. Suppose $\mathcal{R}_0 > 1$ and $f_1(s) = f_2(s)$. For convenience of notation, we denote $g(x) = x - 1 - \ln x$. It is easy to see that $g(x) \geq 0$ for $x > 0$ and $g'(x) = 1 - \frac{1}{x}$. Furthermore, g has a global minimum at 1 and satisfies $g(1) = 0$. We define a Lyapunov functions as follows :

$$U(t) = U_1(t) + U_2(t) + U_3(t)$$

Where

$$U_1 = T(t) - T^* \ln \frac{T(t)}{T^*} + \frac{1}{\eta_1} \left(T_i(t) - T_i^* \ln \frac{T_i(t)}{T_i^*} \right) + \frac{q}{a\eta_1} \left(T_c(t) - T_c^* \ln \frac{T_c(t)}{T_c^*} \right) + \frac{\beta_1 T^*}{c} \left(V(t) - V^* \ln \frac{V(t)}{V^*} \right),$$

$$U_2(t) = \frac{\beta_1 T^* V^*}{\eta_1} \int_0^\infty f_1(s) e^{-\mu_1 s} \int_{-s}^0 g \left(\frac{T(t+\tau)V(t+\tau)}{T^*V^*} \right) d\tau ds + \frac{\beta_2 T^* T_i^*}{\eta_1} \int_0^\infty f_1(s) e^{-\mu_1 s} \int_{-s}^0 g \left(\frac{T(t+\tau)T_i(t+\tau)}{T^*T_i^*} \right) d\tau ds$$

and

$$U_3(t) = \frac{\beta_1 T^* V^*}{\eta_4} \int_0^\infty f_4(s) e^{-\mu_3 s} \int_{-s}^0 g \left(\frac{T(t+\tau)T_i(t+\tau)}{T_i^*} \right) d\tau ds.$$

Calculating the time derivative of U_1, U_2 and U_3 along the solutions of system (1), we have

$$\begin{aligned} \frac{dU_1}{dt} &= \left(1 - \frac{T^*}{T} \right) [b - \delta T - \beta_1 TV - \beta_2 TT_i] \\ &+ \frac{1}{\eta_1} \left(1 - \frac{T_i^*}{T_i} \right) \left(\int_0^\infty f_1(s) e^{-\mu_1 s} \beta_1 T(t-s)V(t-s) ds + \right. \\ &+ \left. \int_0^\infty f_1(s) e^{-\mu_1 s} \beta_2 T(t-s)T_i(t-s) ds - \mu_1 T_i - qT_i T_c \right) \\ &+ \frac{q}{a\eta_1} \left(1 - \frac{T_c^*}{T_c} \right) [\lambda + aT_i T_c - \alpha T_c] \\ &+ \frac{\beta_1 T^*}{c} \left(1 - \frac{V^*}{V} \right) \left(\int_0^\infty kT_i(t-s)f_4(s) e^{-\mu_3 s} ds - cV \right) \\ &= b - \delta T - \beta_1 TV - \beta_2 TT_i - b \frac{T^*}{T} + \delta T^* + \beta_1 VT^* + \beta_2 T_i T^* \\ &+ \frac{1}{\eta_1} \int_0^\infty \beta_1 T(t-s)V(t-s)f_1(s) e^{-\mu_1 s} ds + \frac{1}{\eta_1} \int_0^\infty \beta_2 T(t-s)T_i(t-s)f_1(s) e^{-\mu_1 s} ds \end{aligned}$$

$$\begin{aligned}
& -\frac{\mu_1}{\eta_1}T_i - \frac{q}{\eta_1}T_iT_c - \frac{1}{\eta_1}\frac{T_i^*}{T_i}\int_0^\infty f_1(s)e^{-\mu_1s}\beta_1T(t-s)V(t-s)ds \\
& - \frac{1}{\eta_1}\frac{T_i^*}{T_i}\int_0^\infty f_1(s)e^{-\mu_1s}\beta_2T(t-s)T_i(t-s)ds + \frac{\mu_1}{\eta_1}T_i^* + \frac{qT_i^*T_c}{\eta_1} \\
& + \frac{q}{a\eta_1}\left(\lambda + aT_iT_c - \alpha T_c - \lambda\frac{T_c^*}{T_c} - aT_iT_c^* + \alpha T_c^*\right) \\
& + \frac{k\beta_1T^*}{c}\int_0^\infty T_i(t-s)f_4(s)e^{-\mu_3s}ds - \beta_1T^*V + \beta_1T^*V^* \\
& - \frac{k\beta_1T^*}{c}\frac{V^*}{V}\int_0^\infty T_i(t-s)f_4(s)e^{-\mu_3s}ds,
\end{aligned}$$

$$\begin{aligned}
\frac{dU_2}{dt} &= \beta_1TV + \beta_2TT_i - \frac{1}{\eta_1}\int_0^\infty \beta_1T(t-s)V(t-s)f_1(s)e^{-\mu_1s}ds \\
& - \frac{1}{\eta_1}\int_0^\infty \beta_2T(t-s)T_i(t-s)f_1(s)e^{-\mu_1s}ds \\
& + \frac{\beta_1T^*V^*}{\eta_1}\int_0^\infty f_1(s)e^{-\mu_1s}\ln\frac{T(t-s)V(t-s)}{TV}ds \\
& + \frac{\beta_2T^*T_i^*}{\eta_1}\int_0^\infty f_1(s)e^{-\mu_1s}\ln\frac{T(t-s)T_i(t-s)}{TT_i}ds,
\end{aligned}$$

and

$$\begin{aligned}
\frac{dU_3}{dt} &= \beta_1T^*V^*\frac{T_i}{T_i^*} - \frac{\beta_1T^*V^*}{\eta_4T_i^*}\int_0^\infty T_i(t-s)f_4(s)e^{-\mu_3s}ds \\
& + \frac{\beta_1T^*V^*}{\eta_4}\int_0^\infty f_4(s)e^{-\mu_3s}\ln\frac{T_i(t-s)}{T_i}ds.
\end{aligned}$$

Taking the derivative of $U(t)$ and making use of the equations (5) defining the positive equilibrium E^* , we obtain after simplifications :

$$\begin{aligned}
\frac{dU}{dt} &= \delta T^*\left(2 - \frac{T}{T^*} - \frac{T^*}{T}\right) + \frac{q\lambda}{a\eta_1}\left(2 - \frac{T_c}{T_c^*} - \frac{T_c^*}{T_c}\right) + 2\beta_1T^*V^* + \beta_2T^*T_i^* + \frac{\mu_1}{\eta_1}T_i^* \\
& + \frac{q}{\eta_1}T_i^*T_c^* - \beta_1T^*V^*\frac{T^*}{T} - \beta_2T^*T_i^*\frac{T^*}{T} - \frac{1}{\eta_1}\frac{T_i^*}{T_i}\int_0^\infty f_1(s)e^{-\mu_1s}\beta_1T(t-s)V(t-s)ds \\
& - \frac{1}{\eta_1}\frac{T_i^*}{T_i}\int_0^\infty \beta_2T(t-s)T_i(t-s)f_1(s)e^{-\mu_1s}ds - \frac{\beta_1T^*V^*}{\eta_4T_i^*}\frac{V^*}{V}\int_0^\infty T_i(t-s)f_4(s)e^{-\mu_3s}ds \\
& + \frac{\beta_1T^*V^*}{\eta_1}\int_0^\infty f_1(s)e^{-\mu_1s}\ln\frac{T(t-s)V(t-s)}{TV}ds + \frac{\beta_1T^*V^*}{\eta_4}\int_0^\infty f_4(s)e^{-\mu_3s}\ln\frac{T_i(t-s)}{T_i}ds
\end{aligned}$$

ARIMA

$$\begin{aligned}
 & + \frac{\beta_2 T^* T_i^*}{\eta_1} \int_0^\infty f_1(s) e^{-\mu_1 s} \ln \frac{T(t-s) T_i(t-s)}{T T_i} ds \\
 = & \delta T^* \left(2 - \frac{T}{T^*} - \frac{T^*}{T} \right) + \frac{q\lambda}{a\eta_1} \left(2 - \frac{T_c}{T^*} - \frac{T_c^*}{T^*} \right) + \beta_1 T^* V^* + \beta_2 T^* T_i^* \\
 & - \beta_1 T^* V^* \frac{T^*}{T} - \beta_2 T^* T_i^* \frac{T^*}{T} + \beta_1 T^* V^* \ln \frac{T^* V^* T_i}{T V T_i^*} \\
 & + \frac{\beta_1 T^* V^*}{\eta_1} \int_0^\infty f_1(s) e^{-\mu_1 s} \left[1 - \frac{T(t-s) V(t-s) T_i^*}{T^* V^* T_i} + \ln \frac{T(t-s) V(t-s) T_i^*}{T^* V^* T_i} \right] ds \\
 & + \frac{\beta_2 T^* T_i^*}{\eta_1} \int_0^\infty f_1(s) e^{-\mu_1 s} \left[1 - \frac{T(t-s) T_i(t-s)}{T^* T_i} + \ln \frac{T(t-s) T_i(t-s)}{T^* T_i} \right] ds \\
 & + \frac{\beta_1 T^* V^*}{\eta_4} \int_0^\infty f_4(s) e^{-\mu_3 s} \left[1 - \frac{T_i(t-s) V^*}{T_i^* V} + \ln \frac{T_i(t-s) V^*}{T_i^* V} \right] ds \\
 & + \beta_1 T^* V^* \ln \frac{T_i^* V}{T_i V^*} + \beta_2 T^* T_i^* \ln \frac{T^*}{T}, \\
 = & \delta T^* \left(2 - \frac{T}{T^*} - \frac{T^*}{T} \right) + \frac{q\lambda}{a\eta_1} \left(2 - \frac{T_c}{T^*} - \frac{T_c^*}{T^*} \right) - [\beta_1 T^* V^* + \beta_2 T^* T_i^*] g \left(\frac{T^*}{T} \right) \\
 & - \frac{\beta_1 T^* V^*}{\eta_1} \int_0^\infty f_1(s) e^{-\mu_1 s} g \left(\frac{T(t-s) V(t-s) T_i^*}{T^* V^* T_i} \right) ds \\
 & - \frac{\beta_2 T^* T_i^*}{\eta_1} \int_0^\infty f_1(s) e^{-\mu_1 s} g \left(\frac{T(t-s) T_i(t-s)}{T^* T_i} \right) ds \\
 & - \frac{\beta_1 T^* V^*}{\eta_4} \int_0^\infty f_4(s) e^{-\mu_3 s} g \left(\frac{T_i(t-s) V^*}{T_i^* V} \right) ds.
 \end{aligned}$$

According to the property of g , we obtain that $\frac{dU(t)}{dt} \leq 0$. It can be verified that $\frac{dU(t)}{dt} = 0$ if and only if

$$\frac{T}{T^*} = \frac{T_c}{T_c^*} = \frac{T(t-s) V(t-s) T_i^*}{T^* V^* T_i} = \frac{T(t-s) T_i(t-s)}{T^* T_i} = \frac{T_i(t-s) V^*}{T_i^* V} = 1$$

It means that the largest invariant set $\mathcal{M}_0 \subseteq \mathcal{M} = \left\{ (T, T_i, T_c, V) : \frac{dU}{dt} = 0 \right\}$ is the singleton $\left\{ E^* \right\}$. Again by the Lyapunov-LaSalle invariance principle, the chronic infection equilibrium E^* of system (1) is globally asymptotically stable.

5.2.2. Local stability and Hopf bifurcation when $\tau_i = 0, i = 1, 2, 4, \tau_3 \geq 0$.

In this subsection, we consider model (1) with particular distribution functions $f_i(s)$, $i = 1, 2, 3, 4$ as : $f_1(s) = f_2(s) = \delta(s - \tau_1)$, $f_3(s) = \delta(s - \tau_3)$ and $f_4(s) = \delta(s - \tau_4)$, where $\delta(\cdot)$ is the dirac delta function. We consider the special case where $\tau_1 = \tau_2 = \tau_4 = 0$ and $\tau_3 \geq 0$. Then, we obtain that $\eta_1 = \eta_2 = \eta_4 = 1$ and $\eta_3 = e^{-\mu_2\tau_3}$. In this case, the characteristic equation at the equilibrium E^* is

$$\nu^4 + A_3\nu^3 + A_2\nu^2 + A_1\nu + A_0 + [B_3(\tau_3)\nu^3 + B_2(\tau_3)\nu^2 + B_1(\tau_3)\nu + B_0(\tau_3)] e^{-\tau_3\nu} = 0, \quad (9)$$

where

$$\begin{aligned} A_3 &= \frac{b}{T^*} + c + \alpha + \frac{k\beta_1 T^*}{c}, \\ A_2 &= \frac{b}{T^*} \left(c + \alpha + \frac{k\beta_1 T^*}{c} \right) + \beta_2 T^* (\beta_1 V^* + \beta_2 T_i^*) + c\alpha + \frac{\alpha k\beta_1 T^*}{c}, \\ A_1 &= \frac{\alpha b}{T^*} \left(c + \frac{k\beta_1 T^*}{c} \right) + [k\beta_1 + \beta_2(c + \alpha)] T^* (\beta_1 V^* + \beta_2 T_i^*), \\ A_0 &= \alpha T^* (\beta_1 V^* + \beta_2 T_i^*) (k\beta_1 + c\beta_2), \\ B_3(\tau_3) &= -aT_i^* e^{-\mu_2\tau_3}, \\ B_2(\tau_3) &= -aT_i^* e^{-\mu_2\tau_3} \left(\frac{b}{T^*} + \frac{k\beta_1 T^*}{c} + c \right) + aqT_i^* T_c^* e^{-\mu_2\tau_3}, \\ B_1(\tau_3) &= aT_i^* e^{-\mu_2\tau_3} \left[qT_c^* \left(c + \frac{b}{T^*} \right) - \frac{b}{T^*} \left(c + \frac{k\beta_1 T^*}{c} \right) - \beta_2 T^* (\beta_1 V^* + \beta_2 T_i^*) \right], \\ B_0(\tau_3) &= aT_i^* e^{-\mu_2\tau_3} \left[cqT_c^* \frac{b}{T^*} - T^* (k\beta_1 + c\beta_2) (\beta_1 V^* + \beta_2 T_i^*) \right]. \end{aligned}$$

When $\tau_3 = 0$, equation (9) becomes

$$\nu^4 + (A_3 + B_3(0))\nu^3 + (A_2 + B_2(0))\nu^2 + (A_1 + B_1(0))\nu + A_0 + B_0(0). \quad (10)$$

Using the Routh-Hurwitz criterion on (10), we investigate the local stability of E^* . The relevant Routh-Hurwitz determinants are :

$$\begin{cases} \Delta_1 &= A_3 + B_3(0) > 0, \\ \Delta_2 &= (A_3 + B_3(0))(A_2 + B_2(0)) - (A_1 + B_1(0)) > 0, \\ \Delta_3 &= (A_1 + B_1(0))\Delta_2 - (A_3 + B_3(0))^2(A_0 + B_0(0)) > 0, \\ \Delta_4 &= (A_0 + B_0(0))\Delta_3 > 0. \end{cases}$$

Since all the parameters of model (1) are positive, it follows that

$$\Delta_1 = \frac{b}{T^*} + c + \frac{k\beta_1 T^*}{c} + \alpha - aT_i^* = \frac{b}{T^*} + c + \frac{k\beta_1 T^*}{c} + \frac{\lambda}{T_c^*} > 0.$$

ARIMA

Furthermore, by straightforward computations, we show that

$$\begin{aligned}
 \Delta_2 &= \left(\frac{b}{T^*} + c + \frac{k\beta_1 T^*}{c} + \frac{\lambda}{T_c^*} \right) [aqT_i^* T_c^* + \beta_2 T^* (\beta_1 V^* + \beta_2 T_i^*) \\
 &\quad + \frac{b}{T^*} \left(c + \frac{k\beta_1 T^*}{c} \right) + \frac{\lambda}{T_c^*} \left(\frac{b}{T^*} + c + \frac{k\beta_1 T^*}{c} \right)] - aqT_i^* T_c^* \left(c + \frac{b}{T^*} \right) \\
 &\quad - \frac{b}{T^*} \frac{\lambda}{T_c^*} \left(c + \frac{k\beta_1 T^*}{c} \right) - T^* (\beta_1 V^* + \beta_2 T_i^*) \left(k\beta_1 + \beta_2 c + \beta_2 \frac{\lambda}{T_c^*} \right), \\
 &= aqT_i^* T_c^* \left(\frac{k\beta_1 T^*}{c} + \frac{\lambda}{T_c^*} \right) + \frac{b}{T^*} \left(c + \frac{k\beta_1 T^*}{c} \right) \left(\frac{b}{T^*} + c + \frac{k\beta_1 T^*}{c} \right) \\
 &\quad + \frac{\lambda}{T_c^*} \left(\frac{b}{T^*} + c + \frac{k\beta_1 T^*}{c} \right) \left(\frac{b}{T^*} + c + \frac{k\beta_1 T^*}{c} + \frac{\lambda}{T_c^*} \right) \\
 &\quad + T^* (\beta_1 V^* + \beta_2 T_i^*) \left[\beta_2 \left(\frac{b}{T^*} + \frac{k\beta_1 T^*}{c} \right) - k\beta_1 \right] > 0.
 \end{aligned}$$

Thus, all solutions of (10) have negative real parts if and only if

$$\Delta_3 = (A_1 + B_1(0))\Delta_2 - (A_3 + B_3(0))^2(A_0 + B_0(0)) > 0. \quad (11)$$

The stability is given in the following theorem.

Theorem 5.3 Consider system (1) with $\tau_i = 0$, $i = 1, 2, 3, 4$. If $\mathcal{R}_0 > 1$, then the chronic infection equilibrium E^* is locally asymptotically stable provided that (11) holds.

The root of (9) depends on τ_3 continuously. A root of (9) may pass through the imaginary axis and enter the right side when τ_3 increases. Let us consider $\nu = \mu(\tau_3) + i\omega(\tau_3)$ a root of equation (9). We are interested in the change of stability of chronic infection equilibrium E^* , which will occur at the values of τ_3 for which $\mu(\tau_3) = 0$ and $\omega(\tau_3) > 0$. $\nu = i\omega$ is the critical case since a root may enter the right side or the left side under small perturbation when it locates on the imaginary axis. After substituting $\nu = i\omega$ into (9) and separating the real and the imaginary parts, we obtain that

$$\begin{aligned}
 M(\omega) \cos \omega\tau_3 + N(\omega) \sin \omega\tau_3 &= E(\omega), \\
 N(\omega) \cos \omega\tau_3 - M(\omega) \sin \omega\tau_3 &= F(\omega),
 \end{aligned} \quad (12)$$

where

$$\begin{aligned}
 M(\omega) &= B_2(\tau_3)\omega^2 - B_0(\tau_3), & N(\omega) &= B_3(\tau_3)\omega^3 - B_1(\tau_3)\omega, \\
 E(\omega) &= \omega^4 + A_0 - A_2\omega^2, & F(\omega) &= -A_3\omega^3 + A_1\omega.
 \end{aligned}$$

From (12), we can get

$$\cos \omega \tau_3 = \frac{M(\omega)E(\omega) + N(\omega)F(\omega)}{M(\omega)^2 + N(\omega)^2} \quad \text{and} \quad \sin \omega \tau_3 = \frac{N(\omega)E(\omega) - M(\omega)F(\omega)}{M(\omega)^2 + N(\omega)^2}. \quad (13)$$

Squaring and adding (13), we obtain

$$F(\omega, \tau_3) := \omega^8 + C_6(\tau_3)\omega^6 + C_4(\tau_3)\omega^4 + C_2(\tau_3)\omega^2 + C_0(\tau_3) = 0, \quad (14)$$

where

$$\begin{aligned} C_6(\tau_3) &= A_3^2 - 2A_2 - B_3(\tau_3)^2, \\ C_4(\tau_3) &= A_2^2 - 2A_3A_1 + 2A_0 - B_2(\tau_3)^2 + 2B_3(\tau_3)B_1(\tau_3), \\ C_2(\tau_3) &= A_1^2 - 2A_2A_0 - B_1(\tau_3)^2 + 2B_2(\tau_3)B_0(\tau_3), \\ C_0(\tau_3) &= A_0^2 - B_0(\tau_3)^2. \end{aligned}$$

Denote

$$I = \left\{ \omega(\tau_3) > 0 : F(\omega, \tau_3) = 0 \right\},$$

which is a finite set. If $I \neq \emptyset$, then E^* is stable for $\tau_3 \geq 0$. Note that

$$F(0, \tau_3) = A_0^2 - B_0(\tau_3)^2, \quad \lim_{\omega \rightarrow +\infty} F(\omega, \tau_3) = +\infty.$$

In addition, we have

$$\begin{aligned} A_0 + B_0(\tau_3) &= T^*(\beta_1 V^* + \beta_2 T_i^*)(k\beta_1 + c\beta_2)(\alpha - aT_i^* e^{-\mu_2 \tau_3}) + aT_i^* cqT_c^* \frac{b}{T^*} e^{-\mu_2 \tau_3}, \\ &= \frac{\lambda}{T_c^*} T^*(\beta_1 V^* + \beta_2 T_i^*)(k\beta_1 + c\beta_2) + aT_i^* cqT_c^* \frac{b}{T^*} e^{-\mu_2 \tau_3} > 0. \end{aligned}$$

Therefore, if

$$(\mathcal{H}_1) \quad A_0 < B_0(\tau_3)$$

holds, then $I \neq \emptyset$ and $F(\omega, \tau_3) = 0$ has at least one positive solution.

Assume $I = \{\omega_1, \omega_2, \dots, \omega_{j_0}\}$. For $j \in \{1, 2, \dots, j_0\}$, choose the unique angle $\theta_j(\tau_{3j}) \in [0, 2\pi)$ such that

$$\begin{aligned} \cos \theta_j(\tau_{3j}) &= \frac{M(\omega_j)E(\omega_j) + N(\omega_j)F(\omega_j)}{M(\omega_j)^2 + N(\omega_j)^2}, \\ \sin \theta_j(\tau_{3j}) &= \frac{N(\omega_j)E(\omega_j) - M(\omega_j)F(\omega_j)}{M(\omega_j)^2 + N(\omega_j)^2}. \end{aligned} \quad (15)$$

Now, define the function as follows

$$S_n(\tau_{3j}) = \tau_{3j} - \frac{\theta_j(\tau_{3j}) + 2n\pi}{\omega_j(\tau_{3j})}, \quad n \in \{0, 1, 2, \dots\}.$$

Then, the characteristic equation (9) has a purely imaginary root $\nu = i\omega_j(\tau_{3j}^*)$ at delay $\tau_3 = \tau_{3j}^*$ with $\omega_j(\tau_{3j}^*) > 0$ if and only if τ_{3j}^* is a root of function $S_n(\tau_{3j}) = 0$ for some $n \in \mathbb{N}$ and $j \in \{1, 2, \dots, j_0\}$. Thus, the following results come from Theorem 2.2 in [1].

Theorem 5.4 *The characteristic equation (9) admits a pair of simple and conjugate roots $\nu(\tau_{3j}^*) = \pm i\omega_j(\tau_{3j}^*)$, $\omega_j(\tau_{3j}^*) > 0$ at τ_{3j}^* if $S_n(\tau_{3j}^*) = 0$ for some $n \in \mathbb{N}$ and $j \in \{1, 2, \dots, j_0\}$. This pair of simple conjugate pure imaginary roots crosses the imaginary axis from left to right $\delta(\tau_{3j}^*) > 0$ and crosses the imaginary axis from right to left if $\delta(\tau_{3j}^*) < 0$, where*

$$\delta(\tau_{3j}^*) = \text{sign} \left\{ \frac{d\text{Re}\nu}{d\tau_3} \Big|_{\nu=i\omega(\tau_{3j}^*)} \right\} = \text{sign} \left\{ \frac{dS_n(\tau_3)}{d\tau_3} \Big|_{\tau_3=\tau_{3j}^*} \right\} = \text{sign}\{F'_\omega(\omega_j, \tau_{3j}^*)\}.$$

Based on the above analysis, we obtain the following results by Theorem 5.4 and the Hopf bifurcation theorem in [1].

Theorem 5.5 *Consider system (1) with $\tau_i = 0$, $i = 1, 2, 4$ and the special form $f_3(s) = \delta(s - \tau_3)$. Assume that $\mathcal{R}_0 > 1$ and (\mathcal{H}_1) holds. Then, there exists a τ_3^* such that the chronic infection equilibrium E^* is locally asymptotically stable when $0 \leq \tau_3 < \tau_3^*$, and becomes unstable when τ_3 staying in some right neighborhood of τ_3^* . Furthermore, a Hopf bifurcation occurs at $\tau_3 = \tau_3^*$.*

6. Numerical simulations

In this section, we perform numerical simulations for the model (1) with particular distribution functions $f_i(s)$, $i = 1, 2, 3, 4$ as : $f_1(s) = f_2(s) = \delta(s - \tau_1)$, $f_3(s) = \delta(s - \tau_3)$ and $f_4(s) = \delta(s - \tau_4)$, where $\delta(\cdot)$ is the dirac delta function, s_i , $i = 1, 2, 3, 4$ are positive constants. Then, we can see that $\eta_1 = \eta_2 = e^{-\mu_1\tau_1}$, $\eta_3 = e^{-\mu_2\tau_3}$ and $\eta_4 = e^{-\mu_3\tau_4}$. We examine the behavior of the infected steady state E^* using data sets that are commonly used in the literature [8, 16, 18]. Values of parameters are defined as : $b = 10$, $\delta = 0.01$, $\beta_1 = 2.5e - 4$, $\beta_2 = 6.5e - 4$, $\mu_1 = 0.1$, $a = 3e - 2$, $q = 4e - 2$, $k = 100$, $\alpha = 0.15$, $c = 3$, $\lambda = 1$, $\mu_2 = 0.3$ and $\mu_3 = 0.1$. By simple computing when $\mathcal{R}_0 > 1$, the global stability of the chronic infection equilibrium E^* as demonstrated in Theorem 5.2 is numerically shown on Figure 1 for fixed delays $\tau_1 = \tau_2 = 8$, $\tau_3 = 0$ and $\tau_4 = 2.5$.




Figure 1 – Simulation results showing the effect of λ on the dynamics of the model with $\tau_1 = \tau_2 = 3$, $\tau_3 = 0$ and $\tau_4 = 2.5$.

6.1. Effect of CTLs constant production rate

In order to investigate the effect of CTLs production rate, we carry out some numerical simulations to show the contribution of CTLs constant production rate during the whole infection. We set the production rate λ as 0.5, 1, 1.5, 2. We choose $\tau_1 = \tau_2 = 3$, $\tau_3 = 0$ and $\tau_4 = 2.5$. From the four figures of Figure 1, we can observe that uninfected and CTLs cells reach a higher peak level as λ increases. While, the peak level of infected cells and viruses decreases as λ increases. If we interpret the constant rate $\lambda > 0$ as an inflow of antiviral drugs, one can observe from Figure 1 that the entry of antiviral drugs into the host is important as a control parameter in order to reduce the viral load.

6.2. Effect of immune response delay

In order to illustrate our theoretical findings obtained in Theorem 5.5, we simulate model (1) with $\tau_1 = \tau_2 = \tau_4 = 0$ and the special form $f_3(s) = \delta(s - \tau_3)$ with $\tau_3 \geq 0$. First, we set $\tau_3 = 0$ and keep others parameters. We get $E^* = (207.7479, 4.2451, 44.1567, 141.5038)$, $\mathcal{R}_0 = 24.5000$ and $\Delta_3 = 6.0670 > 0$ i.e condition (11) holds. Then, the local stability of the chronic infection equilibrium E^* as established in Theorem 5.3 is numerically shown on Figure 2.

Now, we vary the value of τ_3 more than zero to see the effect of immune response delay. Through numerical calculations, we get two critical values of delay τ_3 , denoted by $\tau_3^* = 0.2683$ and $\tau_3^{**} = 5.5527$. Figure 3 illustrates the local asymptotic stability of E^* for $\tau_3 = 0.2 < \tau_3^*$ as established in Theorem 5.5.




Figure 2 – The time series of model (1) for $\tau_i = 0, i = 1, 2, 3, 4$. The chronic infection equilibrium E^* is asymptotically stable when.




Figure 3 – The time series of model (1) for $\tau_i = 0, i = 1, 2, 4$, and $\tau_3 = 0.2$. The chronic infection equilibrium E^* is asymptotically stable when $\tau_3 < \tau_3^* = 0.2683$.

When we increase the value of immune response delay to $\tau_3 = 0.3 \in (\tau_3^*, \tau_3^{**})$, Figure 4 shows that E^* becomes unstable and system undergoes Hopf bifurcation at $\tau_3 = \tau_3^*$. This latter case is also illustrated on Figure 5 for $\tau_3 = 5.4 \in (\tau_3^*, \tau_3^{**})$.

Now, we increase again the value of immune response delay to $\tau_3 = 5.7 > \tau_3^{**}$. We see from Figure 6 that the chronic infection equilibrium E^* regain its stability for $\tau_3 > \tau_3^{**}$ and Hopf bifurcation occurs at $\tau_3 = \tau_3^{**}$.




Figure 4 – The time series of model (1) for $\tau_i = 0, i = 1, 2, 4$, and $\tau_3 = 0.3$. The chronic infection equilibrium E^* becomes unstable and a Hopf bifurcation occurs when $\tau_3 \in (\tau_3^*, \tau_3^{**})$. Here, $\tau_3^{**} = 5.5527$.




Figure 5 – The time series of model (1) for $\tau_i = 0, i = 1, 2, 4$, and $\tau_3 = 5.4$. The chronic infection equilibrium E^* becomes unstable and a Hopf bifurcation occurs at $\tau_3 = \tau_3^*$.

6.3. Effect of intracellular delays and immune response delay on the dynamics of model (1)

It is challenging to analyze model (1) for the joint effect of four delays theoretically. So, we use numerical simulations to further investigate the effect of intracellular delays




Figure 6 – The time series of model (1) for $\tau_i = 0, i = 1, 2, 4$, and $\tau_3 = 5.7$. The chronic infection equilibrium E^* becomes stable when $\tau_3 > \tau_3^{**} = 5.5527$.

and immune response delay on the dynamics of model when $\tau_i > 0, i = 1, 2, 3, 4$. To this end, we choose $\tau_4 = 2.5$ and $\tau_1 = \tau_2$. Figure 7 plots the chronic infection equilibrium E^* when τ_1 varies and $\tau_3 = 5$ is fixed. From this figure, we see that for fixed immune response delay, when we increase the intracellular delay for both virus-to-cell and cell-to-cell infections, the trajectories of model (1) evolve from unstable to stable state. A similar result is observed in Figure 8 when we fix intracellular delay ($\tau_1 = 3$) and vary immune response delay τ_3 . These figures demonstrate that the chronic infection equilibrium E^* destabilizes as τ_1 and τ_3 decreases. Therefore, an increase in the intracellular delay or the immune response delay can stabilize the infected steady state E^* .

7. Conclusion

In this paper, we have investigated the dynamical properties of a delayed HIV-1 infection model with both virus-to-cell and cell-to-cell transmissions, and CTL immune response delay. This model extends some previous models and also take into account of a rate of CTLs cells exported from thymus. We have derived the basic reproductive number, \mathcal{R}_0 and we have shown that its value allow to determine the global dynamics of model. We have established that when the basic reproductive number \mathcal{R}_0 is less than unity, there is a disease free equilibrium E_0 which is globally asymptotically stable ; while when the basic reproductive number \mathcal{R}_0 is greater than unity, there exists an unique chronic infection equilibrium E^* which is globally asymptotically stable in absence of immune response delay. Furthermore, we have explored the local stability of the chronic infection equilibrium for the special case with only immune response delay. We have determined some




Figure 7 – Simulation results showing the effect of intracellular delay τ_1 when immune response delay is fixed ($\tau_3 = 5$).

conditions leading to the occurrence of Hopf bifurcation and found that when immune response delay increase, there are stability switches of the chronic infection equilibrium. Since it is challenging to analyze model (1) for the joint effect of four delays theoretically, numerical simulations were used to further investigate the infected steady state and the existence of the Hopf bifurcation when $\tau_i > 0$, $i = 1, 2, 3, 4$. We have observed that for fixed immune response delay, when intracellular delay increase, there is also stability switches of the chronic infection equilibrium. these analysis reveal that the sustained oscillations occur when the intracellular delays and immune delay are incorporated simultaneously in the model. These results have enriched our understanding of the effects of production delay in a viral infection processes and its interaction with immune response.




Figure 8 – Simulation results showing the effect of immune response delay τ_3 when intracellular delay τ_1 is fixed ($\tau_1 = 3$).

Meanwhile, the analysis helps us to understand how intracellular incubation period in the virus-to-cell and cell-to-cell infection, virus replication delay and immune response delay affect the cell-virus-immune system dynamics. As far as future investigations are concerned, we are planning to study local stability and Hopf bifurcation of the chronic infection equilibrium in a general case with all delays being positive. This possible extension on which we are already working will be more complex and bigger challenge in the future.

8. Bibliographie

- [1] E. Beretta, Y. Kuang, Geometric stability switch criteria in delay differential systems with delay dependent parameters, *SIAM J. Math. Anal.*, **33** (2002) 1144–1165.
- [2] S. Bonhoeffer, R. M. May, G. M. Shaw, M. A. Nowak, Virus dynamics and drug therapy, *Proc. Natl. Acad. Sci. USA*, **94** (1997), 6971–6971.
- [3] A.M. Elaiw, A.A. Raezah, A.S Alofi, Stability of delay-distributed virus dynamics model with cell-to-cell transmission and CTL immune response, *J. Comp. Anal. Appl.*, **25** (2018), 1518–1531.
- [4] J. K. Hale, P. Waltman, Persistence in infinite-dimensional systems, *SIAM J. Math. Anal.*, **20** (1989), 388–395.
- [5] V. Herz, S. Bonhoeffer, R. Anderson, R. May, M. Nowak, Viral dynamics in vivo : Limitations on estimates of intracellular delay and virus decay, *Proc. Natl. Acad. Sci. USA*, **93** (1996), 7247–7251.
- [6] P. Katri, S. Ruan, Dynamics of human T-cell lymphotropic virus I (HTLV-I) infection of CD4+ T-cells, *C. R. Biologies*, **327** (2004), 1009–1016.
- [7] X. Lai, X. Zou, Modeling HIV-1 virus dynamics with both virus-to-cell infection and cell-to-cell transmission, *SIAM J. Math. Anal.*, **74** (2014), 898–917.
- [8] D.F. Nkoa Onana, B. Mewoli, D.A. Ouattara, Excitability in the host-pathogen interactions of HIV infection and emergence of viral load blips, *J. theor. Biol.*, **317** (2013), 407–417.
- [9] M. A. Nowak, S. Bonhoeffer, A. M. Hill, R. Boehme, H. C. Thomas, H. Mcdade, Viral dynamics in hepatitis B virus infection, *Proc. Natl. Acad. Sci. USA*, **93** (1996), 4398–4402.
- [10] A. S. Perelson, P. W. Nelson Mathematical analysis of HIV-I dynamics in vivo, *SIAM Rev.*, **41** (1999), 3–44.
- [11] A. S. Perelson, D. E. Kirschner, R. de Boer, Dynamics of HIV infection of CD4+ T-cells, *Math. Biosc.*, **114** (1993), 81–125.
- [12] A. S. Perelson, A. U. Neumann, M. Markowitz, J. M. Leonard, D. D. Ho, HIV-1 dynamics in vivo : Virion clearance rate, infected cell life-span, and viral generation time, *Science*, **271** (1996), 1582–1586.
- [13] N. Tarfulea, A mathematical model for HIV treatment with time-varying antiretroviral therapy, *International Journal of Computer Mathematics*, **88** (2011) 3217–3235.

- [14] N. Tarfulea, A. Blink, E. Nelson, D. Turpin, A CTL-inclusive mathematical model for antiretroviral treatment of HIV infection, *Int. J. Biomath.*, **4** (2011) 1–22.
- [15] C. Vargas-De-Leon, Global properties for a virus dynamics model with lytic and non-lytic immune responses, and nonlinear immune attack rates, *J. Biol. Syst.*, **22** (2014), 1–14.
- [16] J. Wang et al., Threshold dynamics of HIV-1 virus model with cell-to-cell transmission, cell-mediated immune responses and distributed delay, *Appl. Math. Comp.*, **291** (2016), 149–161.
- [17] L. Wang, M. Y. Li, D. Kirschner, Mathematical analysis of the global dynamics of a model for HTLV-I infection and ATL progression, *Math. Biosci.*, **179** (2002), 207–217.
- [18] Y. Yang, L. Zou, S. Ruan, Global dynamics of a delayed within-host viral infection model with both virus-to-cell and cell-to-cell transmissions, *Math. Biosci.*, **270** (2015), 183–191.
- [19] Z. Yuan, X. Zou, Global threshold dynamics in an HIV virus model with nonlinear infection rate and distributed invasion and production delays, *Math. Biosc. Eng.*, **10** (2013), 483–498.